Lv4
520 积分 2023-08-21 加入
O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab
13天前
已完结
Antibody–drug conjugates come of age in oncology
1个月前
已完结
Antisense technology: an overview and prospectus
1个月前
已完结
Givosiran in acute intermittent porphyria: A personalized medicine approach
1个月前
已完结
STING activation and overcoming the challenges associated with STING agonists using ADC (antibody-drug conjugate) and other delivery systems
1个月前
已完结
RNAi-based drug design: considerations and future directions
1个月前
已完结
RNA-targeting and gene editing therapies for transthyretin amyloidosis
2个月前
已完结
Transthyretin: the servant of many masters
2个月前
已完结
Cardiac Amyloidosis Due to Transthyretin Protein
2个月前
已完结
Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensus
2个月前
已完结
皖公网安备34019202002308
